Braxia Scientific CEO Dr Roger McIntyre joined Steve Darling from Proactive to share news the company is reporting preliminary results from the Phase 2 randomized clinical trial to evaluate the feasibility, safety, tolerability and efficacy of multidose psilocybin-assisted therapy for treatment-resistant depression.
Dr McIntyre told Proactive the study showed clinically meaningful improvements in depression severity. Complete analysis of antidepressant efficacy and secondary outcomes pending; this trial will be completed by December, 2022, at which point the full analysis will be completed and submitted for publication.